Protalix BioTherapeutics (PLX) Current Deferred Revenue (2010 - 2025)

Protalix BioTherapeutics has reported Current Deferred Revenue for 16 years, with the latest figure at $2.0 million in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue fell 81.88% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2025 stood at $2.0 million (down 81.88% YoY), and the FY2022 full-year result was $13.2 million, up 54.13% from the prior year.
• Current Deferred Revenue for Q1 2025 stood at $2.0 million, down from $12.7 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $18.1 million in Q2 2021, with the low at $2.0 million in Q1 2025.
• Average Current Deferred Revenue over 5 years is $11.0 million, with a median of $11.8 million recorded in 2022.
• Year-over-year, Current Deferred Revenue tumbled 86.54% in 2021 and soared 360.98% in 2022.
• Tracing PLX's Current Deferred Revenue over 5 years: stood at $8.5 million in 2021, then jumped by 54.13% to $13.2 million in 2022, then retreated by 10.53% to $11.8 million in 2023, then increased by 7.68% to $12.7 million in 2024, then slumped by 84.25% to $2.0 million in 2025.
• The last three Current Deferred Revenue figures came in at $2.0 million (Q1 2025), $12.7 million (Q2 2024), and $11.0 million (Q1 2024), per Business Quant data.

Peer Comparison